Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 1,051,536 shares at $4.38 ($4.6M) on 2024-10-21, disclosed to the SEC on 2024-10-22.
Scheduled sale ($4.6M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.38 | 249,728 | $1.1M | 23.7% |
| 2 | $4.38 | 249,728 | $1.1M | 23.7% |
| 3 | $4.38 | 116,696 | $511K | 11.1% |
| 4 | $4.38 | 116,696 | $511K | 11.1% |
| 5 | $4.38 | 159,344 | $698K | 15.2% |
| 6 | $4.38 | 159,344 |
| $698K |
| 15.2% |
| Total | $4.38 avg | 1,051,536 | $4.6M | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |